Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.56 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | DHPS | P49366 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794555 | 0.81 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL12467229 | 0.77 | ADORA2A (0.38) | ADORA2AADORA1EPHB4 | |
| SCHEMBL6073609 | 0.71 | EPHB4 (0.47) | ADORA2AADORA1DPP4EPHB4 | |
| SCHEMBL2253596 | 0.70 | EGFR (0.45) | ADORA2AADORA1DPP4EPHB4ABCG2 | |
| SCHEMBL656145 | 0.70 | FGFR1 (0.56) | ABCG2 | |
| SCHEMBL29229255 | 0.68 | TP53 (0.48) | EPHB4 | |
| SCHEMBL30505593 | 0.68 | TP53 (0.48) | EPHB4 | |
| SCHEMBL654609 | 0.67 | FGFR1 (0.47) | ADORA2AADORA1 | |
| SCHEMBL653492 | 0.67 | CSNK2A1 (0.48) | ABCG2 | |
| SCHEMBL20492668 | 0.66 | FGFR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2405973-A2 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011147753-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2011-12-01 | — | — | WO | disclosed |